Neurocrine says trial of endometriosis treatment met primary endpoint

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Neurocrine Biosciences, Inc. said the dose-finding phase 2 safety and efficacy trial of its proprietary, orally-active small molecule gonadotropin-releasing hormone receptor antagonist (NBI-56418) for endometriosis met its primary endpoint.

The company said results showed a reduction in the composite pelvic sign and symptoms score of greater than five points in the higher dose group (150 mg).

More importantly, the 'worst pain' as measured by the visual analog scale was reduced by an average of 13.1 (placebo), 25.8 (75 mg) and 37.4 (150 mg) during the third month of treatment.

"If these findings are confirmed in subsequent clinical trials, women with endometriosis may one day be able to achieve pain control without suppression of menses and without high risk of bone loss," senior vice president of clinical development Chris O'Brien said in a news release.

The San Diego biopharmaceutical company plans to start a phase 2b study in the fourth quarter of 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.